Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

NTLA - Intellia Therapeutics, Inc. So'nggi... | Finranks

Home

/

NTLA

I

Intellia Therapeutics, Inc. (NTLA)

NGM – Real vaqt narxi. Valyuta: USD

12.09

+0.07 (0.58%)

Bozor ochiq: Aug 12, 2026, 3:26 PM EDT

12.04

+0.02 (0.18%)

Oldingi bozordan keyin: Aug 11, 2026, 7:57 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on August 1, 2026, it awarded inducement grants to eight new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment.

NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues

NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues

Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results.

Intellia Therapeutics Q2 Earnings Call Highlights

Intellia Therapeutics Q2 Earnings Call Highlights

Intellia Therapeutics NASDAQ: NTLA said it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase III results for lonvo-z in hereditary angioedema and the resumption of enrollment in Phase III studies of nex-z for transthyretin amyloidosis.

Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript

Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript

Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.8 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.99 per share a year ago.

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the second quarter ended June 30, 2026.

Videolar

No Data

There is no data to display

Press-relizlar

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on August 1, 2026, it awarded inducement grants to eight new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment.

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the second quarter ended June 30, 2026.